Association of SLC polymorphism and chemotherapy response
Correlation between SLC polymorphism and the effectiveness of response rate and clinical benefits were studied using univariate logistic regression. Supplementary Table 4 shows the relationship between SLC  polymorphism and treatment responses.The individuals showing stable and progressive disease were categorized as non-responders, whereas subjects demonstrating complete or partial response were classified as good responders. Our outcomes showed no association between SLC polymorphisms according to the chemotherapeutic response to platinum-based doublet therapy. As a result, we concluded that none of the SLC polymorphisms might predict chemotherapeutic response or clinical benefit in a significant way.